Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio director Jean Francois Formela, reporting indirect interests in Atlas Venture funds, disclosed sales of 171,405 shares of common stock from June 22–24, 2026 at weighted-average prices between $13.95 and $15.10 under a Rule 10b5-1 trading plan adopted April 8, 2026.
Following these transactions, Atlas Venture funds associated with him reported holding 169,556 shares of Korro Bio common stock indirectly, with Formela disclaiming Section 16 beneficial ownership except for any pecuniary interest.
KRRO reported proposed and recent sales of Common Stock by affiliated holders via Form 144 filings. The excerpt lists multiple sales by Atlas Venture entities, including a sale of 101,579 shares on 06/23/2026 for $1,447,785.17.
Other dated dispositions by Atlas Venture Fund XI and Atlas Venture Opportunity Fund II are shown between 05/28/2026 and 06/23/2026.
Atlas Venture entities filed Rule 144 notices reporting proposed and recent sales of Common Stock of KRRO. The notices list multiple transactions in May–June 2026, including executed sales on 06/22/2026 and 06/23/2026 with share counts and proceeds shown for each trade. The filing also references an earlier private placement by the issuer on 04/22/2024.
KRRO notice of proposed resale activity for Common Stock via Form 144. The filing lists recent sales by selling holders: Atlas Venture Fund XI, L.P. sold 2,441 shares on 05/28/2026 for $34,051.95 and 3,382 shares on 06/22/2026 for $47,178.90. Atlas Venture Opportunity Fund II, L.P. sold 419 shares on 05/28/2026 for $5,845.05 and 580 shares on 06/22/2026 for $8,091.00. The filing also records a prior private placement dated 04/22/2024.
KRRO notice of proposed sales of Common Stock by affiliated holders under Rule 144. The excerpt lists four completed sale entries by Atlas entities with share counts and gross proceeds on 05/28/2026 and 06/22/2026
The filing also references a Private Placement on 03/23/2023 by the issuer for cash and identifies Merrill Lynch at 555 California Street as a listed broker contact.
KRRO filed a Form 144 reporting proposed sales of Common Stock. The filing lists sales by institutional holders including Atlas Venture Fund XI: 2,441 shares for $34,051.95 and Atlas Venture Opportunity Fund II: 419 shares for $5,845.05, each dated 05/28/2026. The filing also references a private placement dated 03/23/2023.
KRRO reports a proposed resale of 3,661 shares of Common Stock under a Form 144, with the notice dated 06/22/2026 and the securities listed for sale on Nasdaq. The filing notes these shares were originally issued in a Private Placement on 04/22/2024.
The excerpt also discloses recent dispositions: Atlas Venture Fund XI, L.P. sold 2,441 shares on 05/28/2026 for $34,051.95, and Atlas Venture Opportunity Fund II, L.P. sold 419 shares on 05/28/2026 for $5,845.05.
Korro Bio, Inc. Chief Operating Officer Todd Chappell reported the sale of 3,168 shares of common stock on June 16, 2026 at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units granted under the company’s 2023 Stock Option and Incentive Plan. After this tax-related sale, Chappell holds a total of 16,964 shares, which includes 10,066 shares underlying an RSU award scheduled to vest on December 15, 2026, subject to his continued service with the company.
Korro Bio, Inc. Chief Scientific Officer Vincent Loic A reported a sale of 3,418 shares of common stock at a weighted-average price of $10.83 per share. According to the disclosure, this was a mandatory sale solely to satisfy tax withholding obligations from vesting of a restricted stock unit granted under the 2023 Stock Option and Incentive Plan.
After this tax-related transaction, he holds 18,297 shares of common stock, including 10,858 shares issuable upon settlement of an RSU that is scheduled to vest on December 15, 2026, subject to continued service with the company.
Korro Bio, Inc. General Counsel Jeffrey Cerio reported an open-market sale of 6,609 shares of common stock at a weighted-average price of $10.83 per share. According to the filing, this was a mandatory sale solely to satisfy tax withholding obligations from vested restricted stock units under the 2023 equity plan.
After this transaction, Cerio holds 35,293 shares directly, including 20,951 shares underlying restricted stock units that are scheduled to vest on December 15, 2026, if his service with the company continues through that date.